Payer formulary tier increases of apixaban: how patients respond and potential implications
S Deitelzweig, E Terasawa, N Atreja… - Current Medical …, 2023 - Taylor & Francis
Objective To assess potential impacts of formulary tier increases of apixaban—an
efficacious oral anticoagulant (OAC) for preventing stroke in patients with atrial fibrillation …
efficacious oral anticoagulant (OAC) for preventing stroke in patients with atrial fibrillation …
Payer formulary exclusions of apixaban: how patients respond and potential implications
S Deitelzweig, E Terasawa, A Kang… - Current Medical …, 2022 - Taylor & Francis
In recent years, US payers have increased usage of formulary exclusions as a means to
help manage costs. Earlier this year, one of the largest pharmacy benefit managers in the …
help manage costs. Earlier this year, one of the largest pharmacy benefit managers in the …
Journey to Anticoagulant Access Following Payer Rejection of Apixaban.
S Deitelzweig, L Xie, E Terasawa… - American Journal of …, 2023 - search.ebscohost.com
OBJECTIVES: To investigate the journey to oral anticoagulant (OAC) access following
formulary-related rejection of apixaban (Eliquis) and evaluate characteristics associated with …
formulary-related rejection of apixaban (Eliquis) and evaluate characteristics associated with …
[HTML][HTML] Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety …
X Li, A Keshishian, M Hamilton, R Horblyuk, K Gupta… - PLoS …, 2018 - journals.plos.org
Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2018 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the US Department of Defense …
BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …
Economic analysis of apixaban therapy for patients with atrial fibrillation from a US perspective: results from the ARISTOTLE randomized clinical trial
PA Cowper, S Sheng, RD Lopes, KJ Anstrom… - JAMA …, 2017 - jamanetwork.com
Importance The Apixaban for Reduction in Stroke and Other Thromboembolic Events in
Atrial Fibrillation (ARISTOTLE) trial reported that apixaban therapy was superior to warfarin …
Atrial Fibrillation (ARISTOTLE) trial reported that apixaban therapy was superior to warfarin …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2020 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
[HTML][HTML] Risk of stroke and bleeding in atrial fibrillation treated with apixaban compared with warfarin
M Bradley, EC Welch, E Eworuke, DJ Graham… - Journal of General …, 2020 - Springer
Background A previous FDA study reported a favorable benefit risk for apixaban compared
with warfarin for stroke prevention in older non-valvular atrial fibrillation (NVAF) patients (≥ …
with warfarin for stroke prevention in older non-valvular atrial fibrillation (NVAF) patients (≥ …
Real-world direct comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Medicare beneficiaries with atrial fibrillation
It remains unknown whether the comparative effectiveness of direct oral anticoagulants
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …
(DOACs) and warfarin differs between atrial fibrillation patients with and without a history of …